Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will ...

Dr. Mekan brings a combined 18 years of experience in hematology and oncology across academic research, clinical practice and biopharmaceutical industry development, and I am excited to welcome her to ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

Shanghai-based VelaVigo has been busy. The biotech granted Avenzo Therapeutics ex-China rights to a Nectin4xTROP2 bispecific ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

WuXi XDC is trading at a price-to-earnings (P/E) ratio of 32 times, a significant premium over WuXi AppTec's 14 times.

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.